Trial | NCT04134143  Report issue

Title

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers
An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft- C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Terminated

  • Study Participants

    6
Some people with diabetes get foot ulcers that do not heal. These ulcers can get infected and cause other medical problems.

Five patients with these foot ulcers volunteered to participate in the first part of this study (C9T12015, NCT02657876). They are called Cohort 1 in this registration. Cohort 1 received one application (piece) of an experimental skin tissue to make sure it was safe.

This study will extend the safety test of the experimental skin tissue. It will find out if it is safe to use more than once to cover non-healing ulcers.

This extension will include two more groups, Cohort 2 and Cohort 3. Cohort 2 may get up to 5 applications. Cohort 3 may get up to 10 applications. The number of applications will depend on how well the wound is healing.

Participants will be in the study up to one year.
Study Started
Nov 07
2019
Primary Completion
Nov 25
2020
Study Completion
Dec 30
2020
Last Update
Jan 14
2021

Biological ExpressGraft-C9T1 Skin Tissue

A round patch of experimental skin tissue that the doctor applies over the ulcer

  • Other names: Experimental skin tissue

Cohort 1: One Application Experimental

Participants enrolled in Cohort 1 received one application of experimental skin tissue during the first part of this trial (NCT02657876)

Cohort 2: Up to Five Applications Experimental

Participants enrolled in Cohort 2 may receive up to 5 applications of experimental skin tissue as required for wound healing

Cohort 3: Up to Ten Applications Experimental

Participants enrolled in Cohort 3 may receive up to 10 applications of experimental skin tissue as required for wound healing

Criteria 

Volunteers will be consented. Then there will be a run-in period for the doctor to run some tests. If the tests show the study would be good for the patient, the doctor will enroll them as participants in the trial.

Inclusion Criteria:

To be considered for inclusion, a participant:

Agrees to practice birth control for the duration of the study
Has documented Type 1 or Type 2 diabetes and an HbA1C score of 10 or below
Has protocol-defined sufficient blood pressure and flow to the foot
Has stable medications for 2 weeks before treatment (other than diabetes medications or antibiotics)
Is able and willing to attend scheduled visits and comply with study procedures
If a smoker, agrees to try quitting and will accept counseling for it (Cohorts 2 and 3 only)
Has documented informed consent for study enrollment
Has had an uninfected, appropriately-sized diabetic ulcer on the foot for at least 4 weeks but not more than 1 year

Exclusion Criteria:

The doctor may not consider for inclusion a participant who:

Is pregnant, nursing, or a prisoner
Has had osteomyelitis in the foot with the ulcer in the last 30 days
Has a history of poor compliance
Has received drugs or therapies not allowed per protocol
Has used an investigational product within the last 60 days
Has ever received therapy for the study ulcer with any cell and/or tissue product (CTP)
Has a study ulcer in a condition not appropriate for the study
Has a medical condition or history that, per protocol or in the opinion of the study doctor, might put the safety of the participant in danger
No Results Posted